Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare diseases. The company aims to address unmet medical needs by bringing new therapies to market. Eton competes with other pharmaceutical companies like Aquestive Therapeutics, Fennec Pharmaceuticals, Eyenovia, Verrica Pharmaceuticals, and Evelo Biosciences.
In evaluating Eton's financial efficiency, its Return on Invested Capital (ROIC) is -1.26%, while its Weighted Average Cost of Capital (WACC) is 8.78%. This results in a ROIC to WACC ratio of -0.14. Although negative, Eton's ratio is better than its peers, suggesting it is closer to generating returns that match its cost of capital.
Comparatively, Aquestive Therapeutics has a ROIC of -69.51% and a WACC of 14.86%, leading to a ROIC to WACC ratio of -4.68. Fennec Pharmaceuticals, with a ROIC of -27.37% and a WACC of 7.50%, has a ratio of -3.65, making it the least inefficient among its peers. Despite this, all companies are generating returns below their cost of capital.
Eyenovia's ROIC is -82.43% against a WACC of 15.56%, resulting in a ROIC to WACC ratio of -5.30. Verrica Pharmaceuticals shows a ROIC of -166.93% and a WACC of 17.86%, with a ratio of -9.34. Evelo Biosciences has the lowest efficiency, with a ROIC of -201.37% and a WACC of 9.04%, leading to a ratio of -22.28.
Overall, while Eton Pharmaceuticals is not yet generating returns above its cost of capital, its ROIC to WACC ratio of -0.14 indicates it is performing relatively better than its peers. This suggests potential for improvement in financial efficiency compared to other companies in the sector.
